A Phase 2 interventional study of Dynamic BH3 Profiling and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (AML), sponsored by Dana-Farber Cancer Institute. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute — 7 open to participants now, 11 under way, none of them phase 3. Leukemia, Myeloid, Acute · Dana-Farber Cancer Institute.
Among the 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute, this one is the 8th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 2, reaches primary completion later than 10 of the 10 other live ones, and was the 27th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →7 of the 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 12+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 30 across the 24 interventional studies, 45 across the 3 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
3 of the studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06152809Dana-Farber Cancer InstituteCIML NK Cells With Venetoclax for AML | 2026-11-30 |
| NCT04024761Dana-Farber Cancer InstituteA Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | 2026-12-01 |
| NCT06138587Dana-Farber Cancer InstitutePreemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Leukemia, Myeloid, Acute by Dana-Farber Cancer Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML).
This is a phase 2, single-center, interventional study evaluating the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML). The DBP assay is a flow cytometry-based test (functional biomarker) performed on subject biospecimen (bone marrow aspirate) to measure drug-induced apoptotic priming against a pre-set panel of drugs, which can help to identify potentially effective drug combinations. Eligible participants will undergo biomarker screening, and the Protocol Tumor Board will review DBP results and clinical data to assign treatment. Following subjects on assigned treatment for safety and efficacy is part of the trial. Up to six venetoclax-based combination regimens are available. Participants will continue to receive assigned therapy as long as they are benefiting and tolerating treatment. The study will enroll up to 40 participants for treatment assignments, with up to 75 screened. Study procedures include screening, biomarker testing, treatment, disease response assessments, and follow-up for up to one year after last treatment.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
This study's planned enrollment of 40 is close to the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have a diagnosis by WHO 2006 of one of the following:
Participants must meet the following organ function as defined below:
If female, participant must be either:
For combination venetoclax, azacitidine, and tagraxofusp assignment, must also meet the following organ function criteria:
Exclusion Criteria:
Participants assigned to combination venetoclax, azacitidine, and tagraxofusp are excluded with any clinically significant cardiac disease or abnormalities defined as:
Participants assigned to combination venetoclax, azacitidine, and revumenib are excluded with the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive venetoclax in combination with low-dose cytarabine (Ven/AraC). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.
Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Cytarabine
Participantsreceive venetoclax in combination with gilteritinib (Ven/Gilt). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.
Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Gilteritinib
Participants receive venetoclax, azacitidine, and tagraxofusp (Ven/Aza/Tag). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.
Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Azacitidine (AZA) · Drug: Tagraxofusp
Participants receive venetoclax in combination with decitabine (Ven/Dec). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.
Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Decitabine
Participants receive venetoclax, azacitidine, and revumenib (Ven/Aza/Rev). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.
Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Azacitidine (AZA) · Drug: Revumenib
Participants receive a 28-day-cycle venetoclax and cladribine-based regimen. The low-intensity strategy is intended for participants older than 70 years or medically unfit and consists of venetoclax, cladribine, and low-dose cytarabine. The mid-intensity strategy is intended for fit participants 70 years or younger and consists of venetoclax, cladribine, and mid-dose cytarabine. For the low-intensity strategy, venetoclax is administered on Days 1-21. Cladribine 5 mg/m² is administered daily on Days 1-5, and cytarabine 20 mg is administered twice daily on Days 1-10. Induction may continue for up to two cycles according to response. Venetoclax dose and duration may be modified for tolerability and drug interactions. For the mid-intensity strategy, venetoclax is administered on Days 2-8. Cladribine 5 mg/m² is administered daily on Days 1-5, and cytarabine is administered once daily on Days 1-5 (age-adjusted). Induction may continue for up to two cycles according to response.
Device: Dynamic BH3 Profiling · Drug: Venetoclax · Drug: Cladribine (CLAD)
Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.
Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.
Cytarabine will be tested in combination with venetoclax at different dosing strategies. Low-dose cytarabine will be combined with venetoclax in Arm 1. It is also administered as part of the venetoclax-cladribine-based regimen in Arm 6, at low or mid-intensity dosing based on age and fitness, and will be age-adjusted for safety.
Gilteritinib is administered in combination with venetoclax to participants assigned to Treatment 2 based on DBP findings and confirmation of regimen-specific eligibility.
Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.
Tagraxofusp is administered in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.
Decitabine is administered in combination with venetoclax to participants assigned to Treatment 4 based on DBP findings and confirmation of regimen-specific eligibility.
Revumenib is administered orally and in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.
Cladribine is administered with venetoclax and low- or mid-intensity cytarabine in a combination regimen. ladribine is administered at 5 mg/m² daily on Days 1-5 of a 28-day cycle.
Feasibility Rate of Dynamic BH3 Profiling (DBP)
Feasibility rate is defined as the proportion of participants whose bone marrow specimens are collected and received by the laboratory for DBP testing, for whom the samples are successfully processed and a DBP report is generated.
Time frame: Within 5 days of receipt of a viable sample.
Overall Response Rate (ORR)
ORR is defined as the proportion of participants with relapsed/refractory acute myeloid leukemia (R/R AML) assigned to protocol therapy by the Protocol Tumor Board who achieve complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete count recovery (CRi), according to the European LeukemiaNet (ELN) response criteria for AML. CR requires bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, absolute neutrophil count (ANC) ≥1,000/μL, and platelet count ≥100,000/μL. CRh requires all other CR criteria to be met, with ANC ≥500/μL and platelet count ≥50,000/μL. CRi requires all other CR criteria to be met, but with ANC \<1,000/μL and/or platelet count \<100,000/μL.
Time frame: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).
Reasons for Unsuccessful Assignment to DBP-Guided Therapy
Reasons for unsuccessful assignment to protocol therapy despite available drug nominations from DBP, or participant withdrawal, will be summarized by category using frequencies and percentages.
Time frame: During the screening period (up to 21 days).
Grade 3 or Higher Hematologic Adverse Events Rate
Grade 3 or higher hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
Grade 3 or Higher Non-Hematologic Adverse Events Rate
Grade 3 or higher non-hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher non-hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (anticipated up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
Overall Response Rate (ORR) by Assigned Treatment Regimen
Grade 3 or higher non-hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher non-hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.
Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
Overall Response Rate (ORR) by Each Treatment Regimen
ORR is defined as the proportion of participants with relapsed/refractory acute myeloid leukemia (R/R AML) assigned to protocol therapy by the Protocol Tumor Board who achieve complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete count recovery (CRi), according to the ELN response criteria for AML. CR requires bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, absolute neutrophil count (ANC) ≥1,000/μL, and platelet count ≥100,000/μL. CRh requires all other CR criteria to be met, with ANC ≥500/μL and platelet count ≥50,000/μL. CRi requires all other CR criteria to be met, but with ANC \<1,000/μL and/or platelet count \<100,000/μL.
Time frame: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).
Duration of Response (DOR)
DOR is measured from the time response criteria are first met for CR, CRi, CRh, or complete remission with incomplete platelet recovery (CRp), whichever occurs first, until the first date of objectively documented recurrent or progressive disease. According to the ELN response criteria for AML, CR requires bone marrow blasts \<5%, absence of circulating blasts and extramedullary disease, ANC ≥1,000/μL, and platelet count ≥100,000/μL. CRi meets all other CR criteria but has ANC \<1,000/μL and/or platelet count \<100,000/μL. CRh meets all other CR criteria with ANC ≥500/μL and platelet count ≥50,000/μL. CRp meets all other CR criteria but has platelet count \<100,000/μL with ANC ≥1,000/μL. Recurrent disease is defined as the reappearance of disease following CR, CRh, or CRi, characterized by bone marrow blasts ≥5%, reappearance of blasts in at least two peripheral blood samples collected at least one week apart, or development of extramedullary disease. Disease progression is defined accord
Time frame: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
6-Month Progression-Free Survival (PFS6)
PFS6 is the percent probability estimate at 6 months based on the Kaplan-Meier method. PFS is measured from the start of study treatment to the first documented disease progression or death from any cause, whichever occurs first. Participants alive without disease progression are censored at the date of last follow-up. Disease progression is defined according to the ELN 2017 criteria as a \>50% increase in bone marrow blasts from baseline (with a minimum 15-percentage-point increase for patients with \<30% blasts at baseline), persistent bone marrow blasts \>70% for at least 3 months without the specified hematologic improvement, a \>50% increase in peripheral blood blasts to \>25 × 10⁹/L in the absence of differentiation syndrome, or the development of new extramedullary disease.
Time frame: From the start of study treatment to 6 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).
12-month Progression-Free Survival (PFS12)
PFS12 is the percent probability estimate at 12 months based on the Kaplan-Meier method. PFS is measured from the start of study treatment to the first documented disease progression or death from any cause, whichever occurs first. Participants alive without disease progression are censored at the date of last follow-up. Disease progression is defined according to the ELN 2017 criteria as a \>50% increase in bone marrow blasts from baseline (with a minimum 15-percentage-point increase for patients with \<30% blasts at baseline), persistent bone marrow blasts \>70% for at least 3 months without the specified hematologic improvement, a \>50% increase in peripheral blood blasts to \>25 × 10⁹/L in the absence of differentiation syndrome, or the development of new extramedullary disease.
Time frame: From the start of study treatment to 12 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).
6-month Overall Survival (OS6)
OS6 is the percent probability estimate at 6 months based on the Kaplan-Meier method. OS is defined as the time from start of study treatment to death due to any cause or censored at date last known alive. All surviving participants will be censored at time of final follow up.
Time frame: At 6 months after the start of study treatment
12-month Overall Survival (OS12)
OS12 is the percent probability estimate at 12 months based on the Kaplan-Meier method. OS is defined as the time from start of study treatment to death due to any cause or censored at date last known alive. All surviving participants will be censored at time of final follow up.
Time frame: At 12 months after the start of study treatment
Plan to share: Yes — The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Jacqueline Garcia. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data can be shared no earlier than 1 year following the date of publication
Access criteria: Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Dec 2029, 33 months later.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 33 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute →